The utilization of vesicle-like nanoparticles-siRNA to target YTHDF1 not only enhances the effectiveness of anti-PD1 therapy in microsatellite instability-high CRC but also overcomes anti-PD1 resistance in microsatellite stable CRC [163]. The gene discussed is YTHDF1; the disease is colorectal carcinoma.